Indaptus Therapeutics (INDP) Receives Notice of Allowance for Strategic Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 15, 2021 7:00 AM EDTNEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Companys platform technology.
The patent, titled, Methods of Treatment of Infections Using Bacteria, (Application No. 16/584,644) provides broad protection for the application of the Companys platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
... More